닫기
검색

ADC

Chase two hares with ADC (Antibody-Drug Conjugate)

 

ADC_fin@2.png

We must admit that cancers are smarter than us. Time is our biggest enemy when fighting against cancers because cancers under attack change themselves or their environments over time to survive. Such changes become the main reason for cancer drug resistance.

We need a blitz attack that could kill cancers before they mutate, hide, or find a way to avoid. From experience, though, we are aware that the attack should be safe and tolerable. Safe blitz attack. Sounds contradictory?

Chase two hares with ADC.

When our antibody designed for ADC meets PREXISE™-L, a patent-protected, proprietary linker platform technology that enables site-specific conjugation of various payloads to an intact antibody, the contraction becomes a reality.

PREXISE™-L is an Fc-III peptide (FcBP) incorporating the non-natural amino acid, p-benzoylphenylalanine or pBpa, for a photoaffinity cross-linking reaction of the peptide with an intact IgG antibody. Ultraviolet radiation of 365nm induces the covalent bonding of PREXISE™-L with Met252 of IgG antibody in a site-specific manner, resulting in a stable control of drug-to-antibody ratio (DAR). PREXISE™-L applies to the conjugation of highly diverse payloads spanning from small molecules to proteins including immunotoxins, providing extensive strategic options for the design of multi-modal ADCs.

For further information about PREXISE™-L, please see our publication here.